EGFR+ Lung Cancer

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.

The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Pretreatment with dexamethasone significantly reduced infusion-related reactions in patients receiving amivantamab for advanced lung cancer, according to findings from the SKIPPirr study.

Byoung Chul Cho, MD, PhD, discussed findings from cohort C of the CHYRSALIS-2 study exploring amivantamab plus lazertinib in patients with non–small cell lung cancer with uncommon EGFR mutations.

Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.

Suresh S. Ramalingam, MD, discussed the practice-changing findings and implications of the phase 3 LAURA study investigating osimertinib for the treatment of patients with EGFR-mutated non–small cell lung cancer.

Nicolas Girard, MD, PhD, discussed findings from the PALOMA-2 study investigating subcutaneous vs intravenous amivantamab plus lazertinib for previously untreated, EGFR-mutant non–small cell lung cancer.

Findings from the MARIPOSA trial showed that amivantamab plus lazertinib were superior to osimertinib for the treatment of EGFR-mutant non–small cell lung cancer.

Xiaolin Zhang, PhD, discusses findings from the phase 2 study exploring a novel oral agent for the treatment of EGFR-mutated non–small cell lung cancer.

Patritumab deruxtecan has been issued a complete response letter to its biologics license application for the treatment for patients with advanced non-small cell lung cancer with EGFR mutations after prior treatment with 2 or more lines of therapy.

A biologics license application for subcutaneous amivantamab combined with recombinant human hyaluronidase has been submitted to the FDA for NSCLC indications.

Osimertinib given after chemoradiation in patients with advanced non–small cell lung cancer harboring a EGFR mutation showed significant benefits.

Suresh Ramalingam, MD, principal investigator of the phase 3 LAURA trial, explains the study's evaluation of osimertinib in EGFR-mutated non-small cell lung cancer.

During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.

During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.

Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.

Though osimertinib is the preferred frontline approach to treatment for those with non-small cell lung cancer with classic EGFR mutations, acquired resistance mechanisms invariably develop.

According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Amivantamab plus carboplatin and pemetrexed is now an approved first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Osimertinib shows significant progression-free survival improvement in stage III EGFR-mutated non-small cell lung cancer post-chemoradiotherapy, marking a major advance in treatment options for this patient population.

The FDA has approved the combination of osimertinib plus chemotherapy for the treatment of EGFR-mutated non-small cell lung cancer.

Participants in virtual events discussed the key issue of whether to initiate therapy immediately or wait for test results that could show the best approach in patients with advanced lung cancer.